

# ***Arschang Valipour - Phenotyping in COPD: Tailoring treatment to each patient***

## **Select podcast references**

- Bakeer M, et al. *Ann Transl Med* 2020;8:1472. (COPD phenotypes and non-pharmacological treatments)
- Buhl R, et al. *Adv Ther* 2020;37:3486–3499. (LAMA/LABA vs. monotherapy for COPD symptoms)
- Chalmers J, et al. *Eur Respir J* 2020;4:20000351. (ICS in specific subgroups of COPD patients)
- Ciciliani A, et al. *Int J Chron Obstruct Pulmon Dis* 2017;12:1565–1577. (Inspiratory flow rates for inhalers)
- Currow D, et al. *Respir Res* 2020;75:50–56. (Low dose morphine for chronic breathlessness)
- Dekhuijzen PN, et al. *Patient Prefer Adherence* 2016;10:1561–1572. (Inhaler mechanisms)
- Gold Initiative for Chronic Obstructive Lung Disease 2021. (LAMA/LABA for symptomatic COPD patients)
- Koblizek V, et al. *Eur Respir J* 2017;49:1601556 and supplementary. (COPD phenotypes in CEE)
- O'Donnell et al. *Eur Respir J* 2017;49:pii: 1601348. (LAMA/LABA vs. monotherapy on physical activity)
- Sulaiman I, et al. *Am J Respir Crit Care Med* 2017;195:1333–1343. (Dry powder inhalers)
- Usmani, et al. <https://www.guidelines.co.uk/respiratory/inhaler-choice-guideline/252870.article> (Inhaler Choice Guidelines)
- Valipour A, et al. *J Thorac Dis* 2018;10:S2780–S2796. (Valve therapy for COPD patients)